Últimas noticias sobre Guardant Health (NASDAQ:GH) Bolsa

Guardant Health

Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Equities

News

Markets

ETFs

$BTC

ARKF

ARKG

ARKK

ARKW

COIN

EXAS

PLTR

PSNL

VRTX

El miércoles, Cathie Wood, a la cabeza de Ark Invest, realizó algunas operaciones significativas, siendo las más destacadas las de Coinbase Global Inc (NASDAQ:COIN) y Palantir Technologies Inc (NYSE:

Movimientos clave de Cathie Wood: ¿qué hay detrás de las últimas operaciones de Ark Invest?

Guardant Health Inc

HSBC BANK 30/10/26 WNT

Gresham Technologies PLC

Grand Havana Inc

Glass House Brands Inc Warrants (15/01/2026)

Glass House Brands Inc

Graham Holdings Co

Galaxy Heroes Coin

Collaborative Investment Series Trust Goose Hollow Hedged Equity ETF

GreenTree Hospitality Group Ltd. American depositary shares, each representing one Class A ordinary share

GreenTree Hospitality Group Ltd

GUANHUA CORPORATION by GuanHua Corporation

GuanHua Corp

Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests

Greystone Housing Impact Investors LP

Gamehost Inc

GREEN AND HILL INDUS INC by Green and Hill Industries, Inc.

Green and Hill Industries Inc

Gores Holdings IX, Inc. - Class A Common Stock

Gores Holdings IX Inc

Greenhill & Co Inc Com

Guild Holdings Company Class A Common Stock

Guild Holdings Co

Graham Corp

Accredited Solutions Inc

Collaborative Investment Series Trust Goose Hollow Multi-Strategy Income ETF

GHO - United States Dollar

Ghost

GOLD HUNTER RES INC by GOLD HUNTER RES INC

Gold Hunter Resources Inc

GOLDEN HORSE MINERALS LTD by GOLDEN HORSE MINERALS LTD

Golden Horse Minerals Ltd

GH Research PLC

GREENHEART GOLD INC by GREENHEART GOLD INC.

GUARDION HLTH SCIENCS INC by Guardion Health Sciences, Inc.

Guardion Health Sciences Inc

GHST World Inc

Aavegotchi - United States Dollar

Goose Hollow Tactical Allocation ETF

G-H-3 INTERNATIONAL INC by G-H-3 International, Inc.

G-H-3 International Inc

GoldHaven Resources Corp Ordinary Shares

GOLDHAVEN RESOURCES CORP by GoldHaven Resources Corp

GoldHaven Resources Corp

GamerCoin

PGIM Global High Yield Fund, Inc

Goldman Sachs Access High Yield Corporate Bond ETF

iShares US & Intl High Yield Corp Bond ETF

GOLD HYDROGEN LIMITED by Gold Hydrogen Limited

Gold Hydrogen Ltd

AMD GLOB HY ETF

Oppenheimer analyst Martin Yang maintains Take-Two Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>) with a Outperform and raises the price target from $185 to $190.

Price Target

Analyst Ratings

TTWO

Oppenheimer Maintains Outperform on Take-Two Interactive, Raises Price Target to $190

Needham analyst Kyle Peterson maintains Fair Isaac (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>) with a Buy and raises the price target from $1850 to $2500.

FICO

Needham Maintains Buy on Fair Isaac, Raises Price Target to $2500

<a href="https://www.youtube.com/live/8rQlEH86FCM?si=s1GWbEOy5eqm4Jq5" title="https://www.youtube.com/live/8rQlEH86FCM?si=s1GWbEOy5eqm4Jq5">https://www.youtube.com/live/8rQlEH86FCM?si=s1GWbEOy5eqm4Jq5</a>

Federal Reserve

Fed's Powell Says Change In Statement Omitting Confidence Not Meant To Convey Anything About Stickiness Of Inflation; We Have Gained Confidence On Inflation Moving Toward 2%; We Don't Want To Do A Lot Of Forward Guidance; There Is A Fair Amount Of Uncertainty; Saying 'Further Progress' Suggests We Are Setting Up A Test;  The Point Is To Find The Right Pace, Need To Find That As We Go

Oppenheimer analyst Martin Yang maintains AppLovin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) with a Outperform and raises the price target from $180 to $260.

Oppenheimer Maintains Outperform on AppLovin, Raises Price Target to $260

Jefferies analyst Omar Nokta maintains International Seaways (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSW#NYSE">INSW</a>) with a Buy and maintains $66 price target.

INSW

Jefferies Maintains Buy on International Seaways, Maintains $66 Price Target

Organon's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGN#NYSE">OGN</a>) short percent of float has risen 28.4% since its last report. The company recently reported that it has 12.53 million shares sold short, which is 6.51% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.98 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Organon Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731008721_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Organon has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Organon's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Organon's peer group average for short interest as a percentage of float is 4.63%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Looking Into Organon's Recent Short Interest

Nexalin Technology's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NYSE">NXL</a>) short percent of float has risen 30.38% since its last report. The company recently reported that it has 93 thousand shares sold short, which is 1.03% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Nexalin Technology Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731008715_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Nexalin Technology has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Nexalin Technology's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Nexalin Technology's peer group average for short interest as a percentage of float is 2.13%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(NXL) - Analyzing Nexalin Technology's Short Interest

WIIM

MEOH

Methanex shares are trading higher after the company reported better-than-expected Q3 revenue results. UBS maintained a Buy rating on the stock.

Credo Technology Group's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NYSE">CRDO</a>) short percent of float has fallen 6.93% since its last report. The company recently reported that it has 6.94 million shares sold short, which is 4.97% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.99 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Credo Technology Group Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731008710_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Credo Technology Group has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Credo Technology Group's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Credo Technology Group's peer group average for short interest as a percentage of float is 4.51%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

CRDO

Peering Into Credo Technology Group's Recent Short Interest

Oppenheimer analyst Ken Wong maintains HubSpot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) with a Outperform and raises the price target from $625 to $740.

HUBS

Oppenheimer Maintains Outperform on HubSpot, Raises Price Target to $740

Fed's Powell Says Not Ruling It Out Or In, When Asked About 2025 Rate Cut Projections From September

PureCycle Technologies shares are trading lower after the company reported worse-than-expected Q3 EPS results.

Oppenheimer analyst Hartaj Singh maintains Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Outperform and raises the price target from $95 to $105.

GILD

Oppenheimer Maintains Outperform on Gilead Sciences, Raises Price Target to $105

<a href="https://www.youtube.com/watch?v=8rQlEH86FCM">https://www.youtube.com/watch?v=8rQlEH86FCM</a>
&nbsp;

Macro Economic Events

Econ #s

Economics

Fed Chair Powell Says Asking Ourselves Is That Where We Need To Be; Trying To Steer Between Moving Too Quickly And Moving Too Slowly; Trying To Be On A Middle Path; We Think That's Where We Are But That's The Question We Will Be Asking In December; We Are On Path Toward A More Neutral Stance; Will Have To See Where The Data Leaves Us

LGND

Ligand Pharmaceuticals shares are trading higher after the company reported worse-than-expected Q3 financial results and raised its FY24 guidance.

Needham analyst Ryan Koontz maintains AudioCodes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUDC#NASDAQ">AUDC</a>) with a Buy and lowers the price target from $14 to $11.

AUDC

Needham Maintains Buy on AudioCodes, Lowers Price Target to $11

Macro Notification

General

White House Says We Will Keep Surging Aid To Ukraine

Oppenheimer analyst Brian Schwartz maintains Clearwater Analytics Hldg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWAN#NYSE">CWAN</a>) with a Outperform and raises the price target from $31 to $35.

CWAN

Oppenheimer Maintains Outperform on Clearwater Analytics Hldg, Raises Price Target to $35

FIVE

Five Below shares are trading higher. Truist Securities raised its price target on the stock from $87 to $88.

<a href="https://www.youtube.com/watch?v=8rQlEH86FCM" title="https://www.youtube.com/watch?v=8rQlEH86FCM">https://www.youtube.com/watch?v=8rQlEH86FCM</a>

Fed Chair Powell Says Since Sept Meeting In The Main Economic Activity Data Has Been Stronger; Overall Take Away A Sense That Downside Risks Of Activity Have Been Diminished; Overall Feeling Good About Economic Activity; Job Report Wasn't Terrible But Was Higher Than Expected; Will Make A Decision On Rates As We Get To December; For December We Will Be Looking At Incoming Data And How That Affects Outlook; In The Process Of Recalibrating From A Fairly Restrictive Level

Guardant Health surges 15% on boosted revenue guidance range, Q3 beats

Check out this evening's top movers from around Wall Street, compiled by The Fly.&nbsp;&nbsp; HIGHER AFTER EARNINGS – AppLovin (APP)&nbsp;up 28.6% ...

Closing Bell Movers: AppLoving up 29% after Q3 earnings beat

Guardant Health, Inc. 2024 Q3 - Results - Earnings Call Presentation

Guardant Health, Inc. (GH) Q3 2024 Earnings Call Transcript

Guardant Health ( ($GH) ) has released its Q3 earnings. Here is a breakdown of the information Guardant Health presented to its investors. Guardant...

Guardant Health Boosts 2024 Revenue Outlook

TD Cowen analyst Daniel Brennan maintained a Buy rating on Guardant Health (GH – Research Report) yesterday and set a price target of $42.00. Danie...

Guardant Health: Strong Financial Performance and Growth Prospects Lead to Buy Rating

Analyst Mark Massaro of BTIG reiterated a Buy rating on Guardant Health (GH – Research Report), retaining the price target of $50.00. Mark Massaro ...

Guardant Health: Strong Financial Performance and Strategic Growth Potential Earns Buy Rating

Aristotle Large Cap Growth Q3 2024 Commentary

Aristotle Core Equity Q3 2024 Commentary

In a report released today, William Bonello from Craig-Hallum reiterated a Buy rating on Guardant Health (GH – Research Report), with a price targe...

Craig-Hallum Remains a Buy on Guardant Health (GH)

ACLS

ADPT

AMAT

ASPN

BMRN

BROS

CPRX

CTVA

DUOL

DXCM

EXPE

FRSH

GOOG

IDXX

KLAC

MELI

MKSI

MTCH

QCOM

RRGB

RXRX

SEDG

SNPS

SRPT

TNDM

TRIP

TSLA

WOLF

Press Releases

Guardant Health to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Guardant Health and Policlinico Gemelli Announce Partnership to Establish A Dedicated In-House Liquid Biopsy Testing Service in Italy

Guardant Health to Share Data at ESMO 2024 Further Demonstrating Strong Performance of Its Precision Oncology Technology in Multiple Advanced Tumor Types

GOZILA Study Published in Nature Medicine Shows Patients With Advanced Cancer Who Receive Liquid Biopsy-Guided Treatment Using Guardant360 CDx Survive Twice as Long

Guardant Health to Report Third Quarter 2024 Financial Results on November 6, 2024

Roberto A. Mignone Joins Guardant Health Board of Directors

Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Colorectal Cancer Screening at ACG 2024

Guardant Health Named to TIME's List of the Best Inventions of 2024

Guardant Health to Participate in Upcoming Investor Conferences

Guardant Health Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

Amedisys

AMN Healthcare Services

Astrana Health

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

Guardant Health

Noticias

Últimas noticias sobre Guardant Health (NASDAQ:GH) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL